TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.9m (down 49% from ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

TG Therapeutics ( (TGTX) ) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

The biopharmaceutical company posted revenue of $83.9 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $80.3 million. TG Therapeutics expects full-year ...